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INTRODUCTION 
  
Acute urinary retention (AUR) is the most common urological emergency 
in patients with benign prostatic hyperplasia.  
Acute urinary retention (AUR) is defined as the sudden and complete 
inability to void urine voluntarily despite the presence of urine in the bladder 
and the desire to urinate. 10% of men in 61 to 70 years age group and 30% in 71 
to 80 years age group would have acute urinary retention in the next five years 
(Curtis et al 2001). Acute urinary retention is the main indication for 25 to 30% 
of the patients undergoing prostatic surgery. 
The event triggering acute urinary retention is not identified in most 
cases. It is the natural history of benign prostatic hyperplasia that progresses to 
spontaneous AUR. Sudden sympathetic stimulation causes an acute rise in the 
smooth muscle tone resulting in urinary retention. Alpha blockers aid in voiding 
by relaxing the smooth muscle tone and relieving obstruction (1).Patient quality 
of life is affected by AUR to the extent that it can be comparable to quality of 
life impaired by acute renal colic (2). Acute urinary retention is usually 
managed by immediate catheterisation and emptying the bladder followed by 
trial without catheter or immediate surgery for benign prostatic hypertrophy. 
Immediate surgery (within few days after AUR) with urinary catheter in situ is 
associated with more complications in the post operative period. Patients on 
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prolonged catheterization without undergoing surgery have to undergo potential 
morbidity in the form of bacterial colonisation the urinary tract, bacteriuria, 
fever and urosepsis with involvement of upper urinary tracts.  
To date the first line of treatment in these patients is giving trial without 
catheter (TWOC) with a prior administration of an alpha blocker that should 
increase the likelihood of success. An initial drained volume of urine less than 
one litre following catheterisation of AUR, patients with less than 60 to 65 years 
of age, a precipitated AUR and catheterisation for more than 3 days would 
increase the chance of successful trial without catheter. Patients undergoing 
TWOC are later subjected to elective transurethral resection of prostate (TURP) 
or continue drug therapy in the form of alpha blockers alone or in combination 
with 5 α reductase inhibitors (5 α RI). 5 α RIs like Dutastride are added to alpha 
blockers if the gland size is above 30cc to reduce the gland size and risk of 
AUR (3).  
In this study effect of tamsulosin has been evaluated in the temporary 
management of acute urinary retention by increasing the rate of successful trial 
without catheter (TWOC) until definitive therapy. Successful TWOC helps 
patient to undergo elective transurethral resection of prostate (TURP) without 
an indwelling urinary catheter or may continue medical therapy if he opts for 
medical therapy over surgery depending on indication. 
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AIM 
To compare the efficacy of tamsulosin and placebo in the immediate 
management of patients with acute urinary retention secondary to benign 
prostatic hyperplasia undergoing trial without catheter and assess effect of 
tamsulosin in the success rate of trial without catheter with respect to 
prostate size, patient age and post void residual.  
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REVIEW OF LITERATURE 
 
 Acute urinary retention (AUR) is the sudden and complete inability to 
void despite having adequate urine in the bladder and the desire (urge sensation) 
to urinate. It is usually be preceded by a history of progressively decreasing 
force of voided stream. An individual may have complaints of lower abdominal 
pain. The bladder has to be drained immediately or it can lead to acute renal 
failure or bladder rupture.  
 
Incidence of AUR in BPH 
  
Incidence of AUR varies from 5 to 25 per thousand person years. It is 
approximately 0.5 to 2.5% annually for BPH patients. This risk increases with 
age and with each year of patient living with symptoms of BPH. For a patient in 
the 50 year age group with mild to moderate BPH symptoms suffering from an 
episode of acute urinary retention, would have 20% chance of undergoing 
subsequent AUR, if he lives upto 80 years of age without intervention. If the 
same patient of 60 years of age lives without intervention, would have 23% of 
chance of recurrent AUR over another 20 years period. A 70 year old patient 
having mild to moderate BPH symptom score with an episode of AUR, would 
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have the 30% chance of suffering from another AUR. The risk of AUR is higher 
in patients suffering from symptomatic benign prostatic hypertrophy. Risk 
factors for AUR in men with symptomatic BPH are elevated serum PSA, large 
prostate volume as measured by transrectal ultrasound (TRUS), Qmax (maximal 
urinary flow rate) and symptom severity (4). 
 In patients in 45 to 49 year age group with mild BPH symptoms with 
IPSS score of 0 to 7, incidence of AUR is from 0.4 per 1000 person-years. In 
patients in 70 to 83 year age group incidence of AUR is 7.9 per1000 person-
years. In Patients with IPSS score 8 to 35, incidence is 3.3 per1000 person-years 
in 45 to 49 years age group. Incidence in patients of symptomatic score of 8 to 
35 in the age group of 70 to 83 years is 11.3/1000 person-years. Patients having 
clinically diagnosed BPH and a BPH symptom score of 8 or greater had the 
largest age adjusted incidence of 13.7 per1000 person-years for AUR (5). 
 
 In the Olmsted County Study (6), evaluation was done based on age, 
severity of symptoms, Qmax (maximum urinary flow rate), and prostate size. 
Study showed incidence rates from 2.6 per 1000 person years for men in their 
40s to 9.3 per 1000 person years for patients with BPH in their seventh decade 
if they had mild symptom score. Study also showed incidence rates from 3.0 per 
1000 person years to 34.7 per 1000 person years, respectively, if same age 
group patients had more than mild symptoms. 
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The relative risk of acute urinary retention is increased with older age, 
moderate to severe BPH symptom scores (3.2 times), Qmax flow rate less 
than12 ml per second (3.9 times), and prostate size more than 30 cc as measured 
by transrectal ultrasound (3.0 times) with comparison as baseline risk of 1.0 
times for the corresponding groups. 
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The incidence raised from 5.6% to 7.7% in BPH patients with a serum 
PSA value less than 1.4 ng/mL and mild to severe symptoms, and from 7.8% to 
10.2% for those with a serum PSA value more than 1.4 ng/mL over the period 
of 4 years in PLESS study (7). 
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ETIOPATHOGENESIS OF AUR IN BPH 
Etiopathogenesis of AUR needs to be evaluated in patients presenting 
with AUR for planning of immediate management and preventing recurrent 
AUR on long term basis. From the clinical management aspect, precipitated 
AUR needs to be differentiated from spontaneous AUR.  Precipitated AUR is 
the sudden inability to pass urine following any precipitating event like any non 
prostatic surgery, temporary urinary catheterization for causes other than AUR, 
anaesthesia and administration of sympathomimetic or anticholinergic drugs or 
drugs having these effects, taking antihistaminic drugs. All other acute urinary 
retentions, without a precipitating factor, are categorised as spontaneous AUR 
(8).  The management of precipitated AUR is different from spontaneous AUR. 
In case of spontaneous AUR, patient would probably have another episode of 
AUR in 15% of cases.75% of these patients with spontaneous AUR would have 
to undergo surgery. In case of a precipitated AUR only 9% would have 
recurrent episodes of AUR and 26% of these patients would have to undergo 
surgery in the long term (8). 
Acute urinary retention causes are categorised in to three groups; any 
event that increases the bladder out flow resistance, interference in neuronal 
pathways supplying the bladder and any event causing bladder over distension 
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(9). The exact mechanism which precipitates acute urinary retention in patients 
with benign prostatic hyperplasia has not been fully understood. The following 
causes may be responsible for precipitation of acute urinary retention in benign 
prostatic hepertrophy. 
Inflammation of the prostate 
Prostatic inflammation is thought to be a causative factor in the 
progression of the disease in BPH, notably the first incident of acute urinary 
retention. Tuncel et al reported a more incidence of inflammation (54.7%) in 
prostatic tissue in patients with AUR than in patients suffering from lower 
urinary tract symptoms alone (28.9%). In the MTOPS study, 1197 patients 
underwent prostate biopsies as base line. Out of 1197 patients, 544 were found 
to have inflammatory changes of acute nature and 513 had inflammatory 
changes of chronic in nature. Patients who found to have inflammation in their 
baseline prostatic biopsies, had bigger prostate gland size and an elevated PSA 
values (known risk factors for AUR) than those found to have no evidence of 
inflammation. These patients with prostatic inflammation were more likely to 
have symptomatic progression or to undergo surgery for BPH. Even in patients 
within placebo group, all the patients who had acute urinary retention, were 
found to have inflammation in their baseline prostatic biopsies. All these 
patients had evidence of inflammatory infiltrates, but these changes could not be 
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correlated to bacterial or other foreign antigens. Prostate secretory products 
were recognised by auto reactive T cells in animal models subjected to 
experimental prostatitis. These findings demonstrated a possible autoimmune 
reaction leading to chronic inflammation in prostate. These infiltrates consist 
mostly of chronically activated CD4 T lymphocytes. These activated CD4 T 
lymphocytes are recruited to the prostate tissue through increased expression of 
interleukin 15 (IL-15) and gamma interferon (IFN-gamma) which are 
inflammatory cytokines predominantly secreted by smooth muscle cells and T 
cells, respectively (10). 
Prostatic infarction 
Spiro and colleagues demonstrated findings of infarction in 85% of 
prostate biopsies operated for acute urinary retention. This is in contrast to 
evidence of prostatic infarction found only 3% in prostatic specimens removed 
from patients with symptoms of lower urinary tract alone (11). Prostatic 
infarction could probably be caused by interference of the intra glandular blood 
supply, any form of injury including iatrogenic and possible infection. The 
correct mechanism causing prostatic infarction resulting in acute urinary 
retention has not been established. A new hypothesis is proposed recently that 
prostatic infarction may lead to swelling and an increase in intraprostatic 
urethral pressure in areas surrounding the zone of infarction. This may in turn 
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stimulate efferent α adrenergic nerves which may result in ultimate increase of 
intraurethral pressure leading to acute urinary retention (12). But another study 
by Anjum and colleagues has established same findings of prostatic infarction 
in men without AUR (35 men present with AUR and without AUR 1.9% vs. 
3.0% respectively). Hence the causative role of infarction of the prostate in the 
pathogenesis of acute urinary retention is questionable (13). 
 
Figure 3, Prostatic infarction role in the AUR development 
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Stromal cell /Epithelial cell ratio and prevention of recurrent AUR 
In a prospective comparative study of pathological prostatic specimens of 
35 men who had AUR in initial presentation with evidence of BPH and 35 
patients who had presented with only refractory lower urinary tract symptoms, it 
was found that those presenting with AUR had a predominant (71%)  epithelial 
component than patients with LUTS only having (60%) epithelial component. 
Differential growth of epithelial component in relation to the stromal 
component may result in ischemic damage (infarction) by decreasing the 
vascular supply of prostatic tissue which may precipitate acute urinary retenton. 
This finding may clarify the effect of 5α reductase inhibitors, which acts by 
preferably reducing epithelial component, can decrease progression of disease, 
there by recurrence of AUR on long term treatment. 
Role of Constipation in AUR 
It is widely considered that constipation can precipitate acute urinary 
retention. Studies found no valid evidence to prove that this can occur in 
patients not having feature of bladder outlet obstruction, evidence of a 
neurological disease or finding of fecal impaction. In the Alfuzosin in Acute 
Urinary Retention (ALFAUR) study, history about their regular bowel habits 
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like constipation was carefully elicited from 363 patients presenting with acute 
urinary retention secondary to BPH. Success of trial without catheter was not 
altered by the presence of constipation history. Therefore a history of 
constipation alone without evidence of faecal impaction should not alter the 
management strategy of patients having acute urinary retention because of BPH. 
But it may provide an indication of how the patient can be managed in the 
longer term with respect to the need for surgical intervention and recurrent 
episodes of AUR. 
Urinary tract infection (UTI) and AUR 
Urinary tract infection in the male may cause AUR or precipitate AUR in 
a patient suffering from BPH or other causes that compromise bladder 
emptying. Stasis caused by poor emptying in a case of bladder outlet 
obstruction may lead to infection. A complete evaluation of voiding function is 
needed when a patient presents with retention and evidence of urinary infection. 
In these cases AUR might be relieved by treatment of UTI along with TWOC 
though the cause of bladder outlet obstruction needs to be addressed to prevent 
recurrent AUR due to recurrent UTI. 
Role of drugs in AUR 
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Drugs with Cholinergic antagonist effects by inhibiting detrusor 
contractility and alpha-adrenergic agonist effects enhancing bladder outlet 
resistance may precipitate urinary retention. Medications having anticholinergic 
actions are used for the treatment of depressive disorders, allergic disorders, 
Parkinson's disease and OAB (over active bladder). α agonists are commonly 
used for cold remedies. In a study by Athanasoupolos et al, it was shown that 
tolterodine drug could be administered safely in combination with α blocker in 
patients with established bladder outlet obstruction by urodynamic studies, 
without causing AUR (14). In their study, Reynard et al. have established that 
use of anticholinergics in men with BPH may lead to a slight rise in the post-
void residual (PVR) which would not significantly increase the risk of acute 
urinary retention (15). Both the agents can be safely given together in the 
management of BPH, especially in patients who have predominant irritative 
voiding symptoms with low post void residual urine. When acute urinary 
retention develops in association with BPH and concomitant use of these drugs, 
management should follow standard procedure. Trial without catheter would be 
appropriate once drug causing retention is withdrawn. 
Role of Non-steroidal anti-inflammatory drugs (NSAIDS) in AUR 
A prospective case control study of BPH patients with more than 45 years 
of age for evaluating the role of NSAID in AUR in the Netherland population 
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established that patients using NSAIDs would have a relative risk of 2.02 for 
developing acute urinary retention than those not taking NSAIDs. Patients who 
were using NSAIDs at a dose more than the recommended daily dose, had the 
highest risk for AUR (odds ratio 3.3). Previous history of use of NSAIDs was 
not associated with increased rate of AUR. NSAIDs have a direct inhibitory 
effect on prostaglandin synthesis (especially PGE2). Prostaglandins especially 
PGE2 play an important role in contractile mechanism of the detrusor muscle in 
the bladder (16). 
MANAGEMENT OF AUR IN BPH 
 Most patients with AUR in BPH can be managed with catheterisation. A 
few cases may require placement of a supra pubic cystostomy in the event of 
failure of urethral foley insertion. Following catheterisation, after few days, 
patient is given trial without catheter. Patient may be hospitalised or treated as 
outpatient. But in patient treatment is required in cases of renal failure, uro-
sepsis, patients with severe co-morbid conditions and patients who may not 
return for regular follow up following catheter placement. 
Duration of catheterisation   
  In their study, Djavan et al evaluated the effect of duration of 
catheterisation in the management of AUR and found that patients who had 
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retention volumes more than 1300 ml benefited most from long term indwelling 
catheters (17). But long term use of indwelling catheters may lead to higher 
incidences of urinary tract infection. 
Complications of prolonged catheterisation 
UTI is the most common nosocomial infection (40%). 80% of hospital 
acquired UTIs are due catheterization. Risk factors for CAUTIs (catheter 
associated UTI-CAUTI) include patients catheterised for more than 6 days, 
patients not taking systemic antibiotics, poor catheter care, female population, 
any active infections in areas other than urinary tract, pre-existing medical 
conditions, malnutrition, chronic kidney disease, catheter insertion in an 
unsterile atmosphere or outside operating room, and keeping drainage tubing or 
urobag placed above the level of the bladder. Risk of development of UTI and 
bacteriuria in patients with an indwelling urinary catheter is approximately 10% 
per day and continues to increase with increasing duration of catheter. Even 
sterile and clean intermittent catheterization has been found to be associated 
with incidence of bacteriuria ranging from 1% to 3% per catheterization. 
Patients kept on indwelling urinary catheter for more than 6 days are found to 
have significantly higher morbidity due to hematuria, urosepsis, lower urinary 
tract infection, asymptomatic bacteriuria, catheter obstruction, prolongation of 
hospitalization for adverse events and urinary leakage around the catheter and 
more hospital stay than in men catheterized for shorter period of time. 
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Complications of prolonged urethral catheterization include urethral stricture 
and meatal stenosis, urethral perforation, and allergic reactions (due catheter 
material) including anaphylaxis. Patients on prolonged indwelling catheters are 
having increased risk of developing stone formation (46% to 53%), bladder 
neck stenosis, urethral erosion and stricture and malignant neoplasms (2.3 to 
10%).  
 
Trial without catheter (TWOC) 
Trial without catheter is given after a short time of 3 or 4 days following 
catheterisation for AUR. Trial without catheter is successful in 23% to 40% of 
cases without any drugs helping TWOC. In case of BPH, TWOC allows the 
patient to remain catheter free until elective surgery planned at a later date. This 
would effectively reduce the morbidity associated with an indwelling catheter 
for the patient and reduce the post operative morbidity after surgery due to 
decreased incidence of catheter associated complications mentioned above.   
Immediate surgery for BPH following AUR would increase perioperative 
complications than elective surgery for same. As bacterial colonization of an 
indwelling urinary catheter is significantly more after catheterization for more 
than 6 days (catheter associated UTI-CAUTI). Successful trial without catheter 
allows patients to undergo elective surgery .To increase the success of TWOC 
in patients with BPH presenting with AUR alpha blockers are added and 
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continued to prevent the recurrence of AUR until patient undergoes definitive 
treatment.  
Justification for α blockers use in TWOC and BPH 
Acute urinary retention in patients with BPH is due to the result of a 
sudden stimulation of α 1 - adrenergic receptors present in the bladder. The 
reason for the use of alpha blockers in BPH is suggested that they act up on the 
“dynamic” component of bladder outlet obstruction (BOO) by relaxing smooth 
muscle elements located in the bladder neck, prostatic urethra, prostate and its 
capsule. This study was done to evaluate and compare the efficacy of 
tamsulosin as compared to placebo in patients with AUR secondary to BPH. 
Miguel Maldonado-Avila etal proved in their prospective randomized 
study, comparing the efficacy of tamsulosin , alfuzosin and placebo in the 
management of acute urinary retention secondary to benign prostatic 
hyperplasia, that TWOC was successful in 28% of patients in the placebo group, 
38% of patients in alfuzocin group and 45% of patients in tamsulosin group, 
after 4 days of catheterisation (18). They also found that tamsulosin was slightly 
more successful than alfuzocin, though statistically not significant.   
In their study S. Alan McNeill et al (19) have evaluated the use of alpha 
blockers in TWOC in the management of acute urinary retention. They found that a 
TWOC following an episode of acute urinary retention, is beneficial by the 
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reducing the number of patients undergoing TURP with an indwelling urinary 
catheter. By using an alpha-blocker following an episode of AUR, chances of 
successful TWOC is increased and may delay or reduce the need for subsequent 
immediate surgical intervention by improving urinary flow rates and decreasing 
post void residual urine. Alpha-blockers may not prevent BPH progression and 
reduce the need for surgery following an episode of AUR. They allow an 
immediate surgical intervention to be planned into an elective procedure by 
increasing the success rate of a TWOC. This may, in turn, reduce the 
perioperative morbidity and mortality observed in patients with AUR who 
undergo TURP with an indwelling catheter. 
The Medical Therapy Of Prostatic Symptoms (MTOPS) (20) trial 
established that α blockers treat symptoms of BPH with a relatively rapid onset 
of action but they do not prevent disease progression of BPH. To prevent 
disease progression an α-blocker is combined with a 5α-reductase inhibitor (5 
ARI) for a short period (3 to 9 months).This is followed by withdrawal of the α-
blocker when 5ARI has established its peak effect and continuation of 5α-
reductase inhibitor monotherapy if patient chooses medical therapy over TURP 
due to various reasons. 
The Symptom Management After Reducing Therapy (SMART-1) study 
(21) evaluated the combined efficacy of dutasteride and tamsulosin. In this 
study men with BPH were randomized to tamsulosin and dutasteride for a 
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period of 24 weeks initially. After 24 weeks, 50% of the patients stopped using 
tamsulosin.
 
84% of the patients with an initial IPS Score of less than 20, had 
sustained improvement in BPH symptoms after placed under 5 ARI 
monotherapy. Therefore, it has been concluded that majority of patients with 
mild to moderate IPSS symptom score may benefit from an initial short period 
(3to9 months) of combination therapy of alpha blockers and 5ARIs followed by 
5ARI monotherapy. 
In all these studies involving various alpha blockers, tamsulosin, 
alfusozin and silodosin are commonly used for increasing the success rate of 
TWOC following an AUR. Their effect varies depending on the prostate size, 
patients age and post void residual. Various studies established the effect of 
these drugs on increasing the success rate of TWOC from 38% to 70%. Some 
studies suggest that addition of alpha blockers before TWOC doubles the 
success rate. This study is done for evaluation of efficacy of tamsulosin in 
TWOC in relation to age, prostate size and post void residual. After successful 
TWOC most of these patients underwent definitive therapy in the form of 
surgery and few of them continued medical therapy due to various reasons.   
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TAMSULOSIN DRUG PROFILE 
Actions 
Tamsulosin competitively blocks α1 adrenoceptors in post synaptic 
junction with relative selectivity to α1A and α1D subtypes. It causes smooth 
muscle relaxation in bladder neck, prostate and prostatic urethra. Tamsulosin 
0.4-mg/day dose showed a fast onset of action in 4 to 8 hours assessed by 
Qmax. Half life is 5 to 10 hours. Tamsulosin 0.4 mg increases the Qmax 
(maximum urinary flow rate). Drug effect on symptoms of BPH is maintained 
for longer periods. It will not prevent disease progression in BPH patients hence 
subsequent AUR but it would delay the need for surgery and reduce the 
incidence of AUR. α 1 blockers can reduce BP by reducing peripheral 
resistance. This effect is not clinically significant for use as an antihypertensive. 
Pharmacokinetics 
Absorption 
Tamsulosin is absorbed rapidly by the intestines and bioavailability is 
complete. Recent meal reduces the drug absorption from intestines. Tamsulosin 
28 
 
shows linear kinetics. In the fed state, after a single dose of Tamsulosin 0.4 mg, 
peak plasma level is attained around 6 hours with steady-state concentrations by 
the fifth day of once daily dose. There is a considerable variation in plasma 
levels with each individual irrespective of dosage. 
Distribution 
99% of ingested tamsulosin is in bound form with plasma proteins. The 
volume of distribution is very less about 0.2L/kg. 
Biotransformation 
Tamsulosin has less first pass metabolism effect, as it is slowly 
metabolized. Most of the ingested tamsulosin is circulating in the blood plasma 
in an unchanged form. CYP450 enzymes in liver metabolize tamsulosin. Dose 
reduction is not required in patients with moderate hepatic insufficiency. 
Excretion 
Majority of the tamsulosin and its metabolic products are excreted in the 
urine. About 9% of drug is excreted without any change. Following a single 
dose, elimination half-life of tamsulosin is about 10  hours. Dose reduction is 
not required in renal insufficiency. 
Indications 
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It is used in the treatment of lower urinary tract symptoms caused by 
bladder outlet obstruction due to BPH. 
Dosage and Administration 
Tamsulosin is taken as once daily dosing either in the day or before going to 
bed. 
Contraindications 
Hypersensitivity or allergic reactions to tamsulosin. 
Patients suffering from orthostatic hypotension or a history of it. 
Chronic decompensated liver disease with liver failure. 
Adverse effects and safety precautions 
Dizziness, and retrograde ejaculation are commonly seen. Postural 
hypotension, palpitations, asthenia and headache are seen in few cases. 
Like other alpha 1 blockers, fall in BP may be seen after treatment with 
Tamsulosin 0.4mg. Hence patient may have giddiness or syncope. If the patient 
develops symptoms or signs of orthostatic hypotension (dizziness, weakness), 
he has to lie down until the disappearance of symptoms. 
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Use of tamsulosin in patients with severe renal impairment (creatinine 
clearance of < 10ml/min) is not advisable as effects on these patients have not 
been studied. 
Intra-operative Floppy Iris Syndrome 
'Intra-operative Floppy Iris Syndrome' (IFIS) is seen in few patients undergoing 
cataract surgery while using tamsulosin along with α1 adrenoceptor antagonists. 
This is characterized by the combination of a flaccid iris that billows in 
response to intra-operative irrigation currents, progressive intra-operative 
miosis, inspiteof pre-operative dilation with mydriatic drugs and potential 
prolapse of the iris toward the phaco-emulsification incisions. The patient's 
ophthalmologist has to use modifications in their surgical technique, like use of 
iris hooks, iris dilator rings, or visco-elastic substances. Discontinuation of α1-
adrenoceptor antagonist therapy prior to cataract surgery may not be beneficial. 
 
Drug Interactions 
Drug interactions have not been seen when Tamsulosin was used 
concomitantly with atenolol, enalapril, and nifedipine. Simultaneous use of 
cimetidine causes a rise, and furosemide causes a fall in the plasma levels of 
tamsulosin, but within the normal range. Hence dose reduction is not required. 
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No interactions at the level of hepatic metabolism have been seen during 
in vitro studies with liver microsomal fractions (representative of the 
cytochrome P450-linked drug metabolizing enzyme system), involving 
amitriptyline, salbutamol, glibenclamide and finasteride. Diclofenac and 
warfarin may increase the elimination rate of tamsulosin. 
Concurrent administration of other α1-adrenoceptor antagonists could 
lead to hypotensive effects. 
Over dosage 
Acute overdose with 5 mg tamsulosin hydrochloride has been reported. 
Acute hypotension (systolic blood pressure 70 mm Hg), vomiting and diarrhoea 
were seen, which were treated with fluid replacement. 
If acute hypotension occurs after over dosage, cardiovascular support has 
to be given. Blood pressure and heart rate could become normal by lying down. 
Volume expanders and vasopressor drugs could be administered. Renal function 
has to be monitored and general supportive measures needs to be given. 
Dialysis is not useful as tamsulosin is highly plasma protein bound. 
When large quantities of tamsulosin are involved, gastric lavage may be 
of useful and activated charcoal and an osmotic laxative, such as sodium 
sulphate, has to be given to reduce drug absorption. 
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MATERIALS AND METHODS 
Prospective study 
Study period – September 2012 to February 2014 
 
Randomised into two groups 
Tamsulosin group A / placebo group B 
 
Tamsulosin group; Patients with acute urinary retention after catheterization 
were given once daily dose of tamsulosin o.4 mg for 4 days.  
Placebo group; Patients with acute urinary retention after catheterization were 
given 4 days of vitamin tablets.  
Success criteria for TWOC; Trial without catheter is considered successful if 
the patient passes urine more than 100 ml with a PVR of less than 200 ml either 
in USG or actually measured by inserting an IFT.   
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Inclusion criteria – 
• Patients with acute urinary retention due to benign prostatic enlargement 
Exclusion criteria – 
•     AUR due to stricture 
•     AUR due to carcinoma prostate or carcinoma bladder 
•     AUR due to hematuria clot retention  
•     AUR due to neurogenic causes 
•     AUR in immediate post operative period ( any surgery) 
•     AUR post TURP (due to early or late complications of  TURP) 
•     Any other previous surgery in bladder neck or urethra or prostate  
•     AUR due to stone disease 
•     Drug induced AUR 
•     AUR due to trauma or spinal cord diseases 
Patients with acute urinary retention after catheterization are to be given 4 
doses of tamsulosin / placebo and given trial without catheter. Trial without 
catheter is considered successful if the patient passes urine more than 100 ml 
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with a PVR of less than 200 ml either in USG or actually measured by inserting 
an IFT. 
 
Follow up 
After 4 doses of tamsulosin / placebo, catheter removed and after patient 
passing urine, actual urine passed is measured and post void is measured using 
USG or IFT. Patient would be planned for TURP and sent to operation theatre 
without an indwelling catheter or would be given alpha blockers with or without 
5-alpha reductase inhibitors depending on the indication.  
 
Statistical analysis; 
Statistical analysis is done using SPSS software. 
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OBSERVATIONS AND RESULTS ANALYSIS 
  About 74 patients were selected for the study and randomly allocated in 
two groups, Group A and Group B, each comprising of 37 patients. Following 
catheterisation patients in group A were given 4 doses Tamsulosin 0.4 mg in 
once daily dosing and 8 - 12 hours after the 4
th
 dose, TWOC given. Group B 
patients were given vitamin tablets for four days and TWOC given same like 
group A. 
Patients selected for both groups were comparable in terms of age group 
and prostate size. 
Age group wise comparison of group A and B 
In age group 1 comprising of patients within 51 years to 60 years, there 
were 18 patients in total (24.3%). In this group there were 7 patients in group A 
(18.9% within group and 9.5% of total) and 11 patients in group B (29.7% 
within group and 14.9% of total). 
Age group 2 comprises of patients with 61 to 70 years age. In this age 
group there were 35 patients in total (47.3%). In this age group there were 16 
36 
 
patients in group A (43.2% within group and 21.6% of total) and 19 patients in 
group B (51.4 % within group and 25.7% of total) 
In age group 3 comprising of patients within 71 to 80 years, there were 21 
patients (28.4%). In this age group there were 14 patients in group A (37.8% 
within group and 18.9% of total). 
Age group wise both group A an B patients were comparable and 
statistically no significant difference among both groups. 
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Chi-square - 3.479. P=  0.176. This infers that  there is no  statistical significance 
exists  between  the  both  group  with respect to  Age  distribution. 
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Chi-square test 
 
Figure4. Age group wise comparison of group A (blue) and B (green) with group 1 - 51 to 
60 years, group 2 – 61 to 70 years, group 3 - 71 to 80 years. 
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Prostate size wise comparison of group A and group B 
  Out of the total 74 patients in the study, 22 patients had grade 1 prostate 
(29.7% of total) and 12 patients were in group A (32.4% within group and 
16.2% of total) and 10 patients were in group B (27% within group and 13.5% 
of total). 38 patients had grade 2 prostate (51.4% of total), out of which 16 were 
in group A (43.2% within group and 21.6% of total) and 22 were in group B 
(59.5% within group and 29.7% of total). 14 patients had grade 3 prostate 
(18.9% of total), out of which 9 were in group A (24.3% within group and 
12.2% of total) and 5 were in group B (13.5% within group and 6.8% of total).  
Both groups were comparable in terms of prostate size as per statistical analysis.   
40 
 
 
Chi square=2.272.  P=0.321. 
There is no statistical significance exists between both groups with respect to prostate size. 
Chi-square test 
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Figure5. Prostate size comparison between Group A (blue) and B (green) 
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RESULTS OF TWOC  
TWOC success comparison between group A and B 
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Chi square= 5.441. P=0.020. 
There exists a statistical significance exists between both groups with respect to Trial  
Without catheter. Among the failure patients (N=40), 37.5% (N=15) patients are in Group A. 
This indicates that the Group A significantly differ from Group B with respect to Trial 
without Catheter. 
From the  below  table ,  There is  3.056  times   odds(risk)  for  Group  B comparative  
to  Group A  with  respect  to  failure of  trial without  catheter.   
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Figure6. TWOC success (0) and failure (1) in group A (blue) and B (green) 
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Above table shows the following data 
1. Average age in group A is 68.06 and in group B is 65.46 with standard deviation of 
7.3 years each. 
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2. Average urine drained after catheterisation for AUR in group A is 667.3 ml with 
standard deviation of 155.3 ml and in group B is 711.08 with standard deviation of 
276.8 ml 
3. Average prostate size by USG of the patients taken for study in group A is 44.19cc 
with standard deviation of 14.76cc and in group B is 40.78 cc with standard deviation 
of 12.8cc 
4. Average urine passed in TWOC in group A is 185.95ml with standard deviation of 
72.59ml and in group B is 161.35ml with standard deviation of 57.65ml 
5. Average PVR after TWOC in group A is 163.51ml with standard deviation of 103.93 
and in group B 212.97ml with standard deviation of 90.49ml. 
The statistical significance (P=0.032) exists only in PVR after TWOC between both 
the groups. 
 
 
 
 
 
 
 
47 
 
Analysis of group A results 
AGE GROUP and TWOC in group A 
 
 
48 
 
 
In group A, total success rate of TWOC is 59.5% and failure rate is 40.5%. 
Age group wise analysis in group A shows the following 
1. Age group 1 (between 51 to 60 years) 6 out of 7 patients had successful TWOC 
(85.7%). 
2. Age group 2 (between 61 to 70 years) 10 out of 16 patients had successful TWOC 
(62.5%). 
3. Age group 3 (between 71 to 80 years) only 6 out of 14 patients had successful TWOC 
(42.9%) and failure (57.1%) is more (8 out of 14) in this age group.  
Chi-square= 3.664.  P= 0.160. Not significant. Age is not a factor for TWOC success in 
group A. 
 
 
 
 
49 
 
 
 
Figure7. Age group wise comparison of TWOC success (blue) and failure (green) in group A 
patients  
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Per rectal Prostate size Grade and TWOC in group A 
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The above results show that in group A  
1. In patients with grade 1 prostate, 11 out of 12 had successful TWOC (91.66%). 
2. In patients with grade 2 prostate 9 out of 16 had successful TWOC (56.25%). 
3. In patients with grade 3 prostate only 2 out of 9 had successful TWOC (22.22%) ie 
TWOC failure (77.78%) is more in these patients. 
Chi-square = 10.409. P value = 0.005. There exists a statistical significant between success 
and failure patients with respect to prostate size grade.   
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Figure8. Prostate size (grade) wise TWOC success (blue) and failure (green) in group A 
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From above, The Mean of Age, USG prostate size, Urine passed TWOC & PVR after TWOC 
are statistically significant between TWOC success and failure.  
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Analysis of group B results 
AGE GROUP and TWOC in group B 
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The above results show that success rate of TWOC in group B is 32.4% and TWOC 
success is uniformly less across all age groups in group B. 
Chi- square= 0.487. P= 0.784, Not significant.  
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Figure9. Age group wise comparison of TWOC success (blue) and failure (green) in group B 
patients  
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Per Rectal Prostate size grade and TWOC in group B 
 
 
Above results show that in group B patients, TWOC is more successful in patients 
with grade 1 prostate (6 out of 10). TWOC failure rate is more in patients with grade 2 
prostate (16 out of 22) and most in grade 3 prostate (0 out of 5).  
58 
 
Chi square= 6.135   P=0.047. There exists a statistical significant between success and 
failure patients with respect to prostate size grade.  
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Figure10. Prostate size (grade) wise TWOC success (blue) and failure (green) in group B. 
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Group B statistics 
 
The  Mean level of  USG Prostate  size, Urine  Passed TWOC  and PVR after  TWOC  
statistically significant between  the TWOC  success and failure  patients in Group B . 
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DISCUSSION 
Management of acute urinary retention (AUR) in patients with benign 
prostatic hyperplasia (BPH) is trial without a catheter (TWOC). After successful 
TWOC, as subsequent risk of AUR is high, patient may undergo TURP 
immediately or electively at a later date. In patients without undergoing any 
treatment recurrence of AUR is 70% within 1 week of first episode (22). In the 
past, AUR was an immediate indication for surgery constituting about 25% to 
30 % of TURPs (23).  
For deciding management, spontaneous AUR needs to be differentiated 
from precipitated AUR. Precipitated AUR is the inability to urinate following a 
trigger cause. These triggering events may be surgery, insertion of indwelling 
urinary catheter, anaesthesia, or usage of drugs with sympathomimetic or 
anticholinergic effects, antihistamines. AUR without a trigger factor are 
categorised as spontaneous. Following an episode of spontaneous AUR, 15% of 
patients had recurrent AUR, and 75% of these patients underwent surgery. 
Following an episode of precipitated AUR, only 9% recurrent AUR, and 26% 
underwent surgery (4) . 
 Patients undergoing TURP immediately following AUR had 
significantly higher rates of complications like re-catheterization (13.8%), 
septicaemia (1.1%) and shock (0.3%) (24).They also had more UTIs, lower tract 
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symptoms and higher medical expenses. Hence the morbidity like catheter 
associated urinary tract infection (CAUTI) increased by the presence of an 
indwelling urinary catheter (25), a trial without catheter is given to patient. 
When TWOC is successful, patient may undergo surgery electively without 
catheter associated morbidity. Alpha blockers like tamsulosin increase the 
TWOC success rate. 
Though alpha blockers increase the success rate of trial without catheter, 
they would not prevent progression of the disease. Patients with significant 
symptoms of frequency, urgency, voiding symptoms and a prostate size of more 
than 30 cc on transrectal ultrasound or a PSA level  more than 1.5 ng/ml are at 
high risk of progression of disease (26). For preventing progression of the 
disease 5 alpha reductase inhibitors (5ARI) are added to alpha blockers. If after 
taking combination therapy for 3 months there are persistent symptoms of 
frequency and urgency, antimuscarinics may be added to treat symptoms of 
over active bladder (26). After a period of time when 5 ARIs have maximal 
effect (9 months), alpha blockers can be withdrawn and patient may be 
monitored clinically (26). If patient is symptomatically better, anticholinergics 
dose reduction or discontinuation may be attempted and patient may be 
continued on 5ARI monotherapy (26). If the patient still has frequency, urgency 
or other voiding symptoms as well as erectile dysfunction, then addition of a 
daily PDE5 inhibitor may be considered (26).  
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If medical therapy is not tolerated or does not improve symptoms, surgery 
is considered.  According to AUA guidelines surgery is recommended in 
patients who complain recurrent gross hematuria of prostatic origin, recurrent 
UTIs, renal dysfuntion secondary to BPH, vesical stones, LUTS refractory to 
other therapies and refractory or recurrent urinary retention.   
Hence alpha blockers are used to increase the TWOC success rate and 
continued to keep the patient catheter free until he undergoes surgery. Patient 
may continue alpha blockers in combination with 5ARIs or anticholinergics 
depending on indications or his option for medical therapy.   
In Lucas et al study (27), success rate of TWOC has been increased to 
52% and recurrence of AUR significantly reduced by administration of alpha 
blocker tamsulosin, when compared with success rate of placebo 34%. In our 
study success rate of tamsulosin group is 59.5% when compared with that of 
placebo group 32.4%. Patients in placebo group had 3 times more risk for 
failure of trial without catheter. 
In another study by Madhu.S.Agarwal etal (28) in india, following AUR 
in BPH, TWOC success rate is 70% in patients given tamsulosin, when same is 
compared with placebo 36%. This success rate with tamsulosin is high when 
compared with our study (59.5%). 
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In their study by Hua etal (29), the success rate of TWOC with 
tamsulosin following an AUR is 61% when compared with control group 28%. 
But in their study efficacy of treatment was not influenced by volume of 
prostate. In our study size of the prostate significantly influenced the success 
rate of trial without catheter both in tamsulosin and placebo group.  
In our study there is statistically significant difference in TWOC success 
in patients given tamsulosin with respect to prostate size. In patients with grade 
1 prostate, 11 out of 12 had successful TWOC (91.66%).In patients with grade 2 
prostate 9 out of 16 had successful TWOC (56.25%). In patients with grade 3 
prostate only 2 out of 9 had successful TWOC (22.22%) ie TWOC failure 
(77.78%) is more in these patients. (P value = 0.005). In MTOPS study (20) 
also, it was established that efficacy of alpha blockers were less effective in men 
with large prostate. 
In their study (30), Fitzpatrik etal found that  age more than 70 years, 
prostate size more than 50 cc, severe lower urinary tract symptoms, drained 
volume at catheterization more than 1000 mL and spontaneous AUR favoured 
TWOC failure whereas catheterization for more than 3 days and α 1 blockade 
before TWOC increased success of TWOC. In our study, in patients given 
tamsulosin, TWOC success rate in 51 to 60 years group is (85.7%) more when 
compared with same (42.9%) in 71 to 80 years age group but it is not 
statistically significant. But prostate size influenced the TWOC success in both 
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tamsulosin and placebo group and that is statistically significant. Patients with 
grade 3 prostate, TWOC failure is more in both tamsulosin and placebo group, 
when compared with grade 1 prostate. These patients had higher TWOC success 
when given tamsulosin (22.22% versus 0%). In our study tamsulosin showed 
higher success rate of TWOC in patients with larger prostate like grade 2 and 
grade 3 prostates. TWOC success rate in placebo group is significantly less in 
these patients. Hence use of tamsulosin in patients presenting with AUR and 
large prostate increases TWOC success rate.  
In our study average post void residual urine after TWOC in patients 
treated with tamsulosin, is 163.51ml (standard deviation of 103.93) and in 
placebo group post void residual urine is 212.97ml (standard deviation of 
90.49ml). This is statistically significant observation. Hence this study 
demonstrated prior administration of tamsulosin significantly reduces post void 
residual urine in trial without catheter. 
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CONCLUSION 
1. Tamsulosin increases the success rate of trial without catheter in patients 
with acute urinary retention. There are 3.056 times odds (risk) for placebo 
group comparative to tamsulosin group with respect to failure of trial 
without catheter. 
2. Prostate size has statistically significant influence on trial without 
catheter. Patients with larger prostate have more chances of failure in trial 
without catheter in both groups. But tamsulosin increases success rate of 
trial without catheter in patients with larger prostate. 
3. Post void residual urine is significantly reduced by addition of tamsulosin 
in patients with acute urinary retention undergoing trial without catheter. 
4. Tamsulosin increases the success rate of TWOC in older age group 
patients with AUR due to BPH compared with placebo. But this is not 
statistically significant in our study.  
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PROFORMA 
A prospective randomized study comparing the efficacy of tamsulosin and 
placebo in the management of acute urinary retention secondary to benign 
prostatic hyperplasia until definitive therapy 
Patient Name:                                                    KMC/GRH                 Date 
Age:                     Sex:                 IP No: 
Complaints  
History  
 Strain to void         Duration-  
AUR duration      
Quantity of urine drained after catheterisation 
Fever  -  Present / Absent 
Hematuria / Calculuria / Dysuria / Pyuria  
LUTS   
Obstructive Voiding symptoms  
Hesitancy          Intermittency         Incomplete emptying        Straining       Postvoid dribbling 
Irritative voiding symptoms  
Urgency  
Frequency                     day                       night                           nocturia        
Urge incontinence                  Incontinence                 type 
Treatment History:  Drugs 
Surgery details 
Catheterisation 
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Past H/O     DM                               HT                                    TB                                    COPD 
Any significant details 
General Examination         
                          fever                 Pallor                obesity         HT             WT 
P/A 
                           
External Genitalia- Penis  
       Scrotum                             
       Testis R 
  L 
Per Rectum –  
Sphincter tone 
Prostate size 
Catheterisation details; 
 
Urine drained; 
Urine quantity passed after TWOC; 
Post void residual after TWOC; 
USG; 
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ABBREVIATIONS 
AUR Acute Urinary Retention 
TWOC Trial With Out Catheter 
TURP Trans Urethral Resection of Prostate 
BPH Benign Prostatic Hypertrophy 
5αRI/5ARI 5 alpha Reductase Inhibitors 
TRUS Trans Rectal Ultra Sound 
PSA Prostate Specific Antigen 
Q max Maximal urinary flow rate 
IPPS International Prostate Symptom Score 
AUA American Urology Association 
LUTS Lower Urinary Tract Symptoms 
UTI Urinary Tract Infection  
CAUTI Catheter Associated Urinary Tract Infection 
OAB Over active Bladder 
NSAIDS Non-Steroidal Anti-Inflammatory Drugs  
BOO Bladder Outlet Obstruction  
BP Blood Pressure 
PVR Post Void Residual urine 
USG Ultra SonoGram 
IFT Infant Feeding Tube 
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